Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Surgery Today
Erschienen in: Surgery Today 9/2017

22.02.2017 | Review Article

History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer

verfasst von: Haruhiko Nakamura, Toshihide Nishimura

Erschienen in: Surgery Today | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Serum biomarkers provide valuable information about the diagnosis and prognosis of a wide variety of malignant tumors. Despite the identification of several useful serum biomarkers in lung cancer, consensus on their utility has not yet been reached. Furthermore, guidelines and standard protocols to implement their use for patients with lung cancer are lacking, despite the accumulation of much data on the efficacy of several serum biomarkers over recent decades. In this review, we discuss the molecular features, functions, and clinical relevance of the conventional serum biomarkers for lung cancer, including carcinoembryonic antigen (CEA), cytokeratin 19 fragment 21-1 (CYFRA 21-1), tissue polypeptide antigen (TPA), carbohydrate antigen 19-9 (CA19-9), sialyl Lewisx (sLex), carbohydrate antigen 125 (CA-125), squamous cell carcinoma-related antigen (SCC-Ag), neuron-specific enolase (NSE), and pro-gastrin-releasing peptide (proGRP), aiming to provide a snapshot of the current landscape and their potential combined utility in the diagnosis and prognosis of lung cancer.
Literatur
1.
Buccheri G, Ferrigno D. Lung tumor markers of cytokeratin origin: an overview. Lung cancer (Amsterdam, Netherlands). 2001;34(Suppl 2):S65–69. (Epub 2001/11/27).CrossRef
2.
Alipoor SD, Adcock IM, Garssen J, Mortaz E, Varahram M, Mirsaeidi M, et al. The roles of miRNAs as potential biomarkers in lung diseases. Eur J Pharmacol. 2016;791:395–404. (Epub 2016/10/23).PubMedCrossRef
3.
Parsons HA, Beaver JA, Park BH. Circulating Plasma Tumor DNA. Adv Exp Med Biol. 2016;882:259–76. (Epub 2016/03/19).PubMedCrossRef
4.
Buccheri G, Torchio P, Ferrigno D. Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments. Chest. 2003;124:622–32. (Epub 2003/08/09).PubMedCrossRef
5.
6.
Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013;32:643–71. (Epub 2013/08/02).PubMedCrossRef
7.
Dykes PW, King J. Carcinoembryonic antigen (CEA). Gut. 1972;13:10001013. (Epub 1972/12/01).CrossRef
8.
Groover JR, Rogers AI. Immunologic tests for the detection of gastrointestinal cancers: status report on carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP). South Med J. 1973;66:1218–21. (Epub 1973/11/01).PubMedCrossRef
9.
Fishman WH, Raam S, Stolbach LL. Markers for ovarian cancer: regan isoenzyme and other glycoproteins. Semin Oncol. 1975;2:211–6. (Epub 1975/09/01).PubMed
10.
Chevinsky AH. CEA in tumors of other than colorectal origin. Semin Surg Oncol. 1991;7:162–6. (Epub 1991/05/01).PubMedCrossRef
11.
Hasegawa T, Isobe K, Tsuchiya Y, Oikawa S, Nakazato H, Nakashima I, et al. Nonspecific crossreacting antigen (NCA) is a major member of the carcinoembryonic antigen (CEA)-related gene family expressed in lung cancer. Br J Cancer. 1993;67:58–65. (Epub 1993/01/01).PubMedPubMedCentralCrossRef
12.
Allard WJ, Neaman IE, Elting JJ, Barnett TR, Yoshimura H, Fritsche HA, et al. Nonspecific cross-reacting antigen 50/90 is elevated in patients with breast, lung, and colon cancer. Cancer Res. 1994;54:1227–34. (Epub 1994/03/01).PubMed
13.
Gold P, Shuster J, Freedman SO. Carcinoembryonic antigen (CEA) in clinical medicine: historical perspectives, pitfalls and projections. Cancer. 1978;42:1399–405. (Epub 1978/09/01).PubMedCrossRef
14.
Steele SR, Chang GJ, Hendren S, Weiser M, Irani J, Buie WD, et al. Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. Dis Colon Rectum. 2015;58:713–25. (Epub 2015/07/15).PubMedCrossRef
15.
Sorensen CG, Karlsson WK, Pommergaard HC, Burcharth J, Rosenberg J. The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence - A systematic review. Int J Surg. 2016;25:134–44. (Epub 2015/12/25).PubMedCrossRef
16.
Vincent RG, Chu TM, Fergen TB, Ostrander M. Carcinoembryonic antigen in 228 patients with carcinoma of the lung. Cancer. 1975;36:2069–76. (Epub 1975/12/01).PubMedCrossRef
17.
Waalkes TP, Abeloff MD, Woo KB, Ettinger DS, Ruddon RW, Aldenderfer P. Carcinoembryonic antigen for monitoring patients with small cell carcinoma of the lung during treatment. Cancer Res. 1980;40:4420–7. (Epub 1980/12/01).PubMed
18.
Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, et al. Tumor markers (CEA, CA 125, CYFRA 21–1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol. 2003;24:209–18. (Epub 2003/12/05).PubMedCrossRef
19.
Pollan M, Varela G, Torres A, de la Torre M, Ludena MD, Ortega MD, et al. Clinical value of p53, c-erbB-2, CEA and CA125 regarding relapse, metastasis and death in resectable non-small cell lung cancer. Int J Cancer. 2003;107:781–90. (Epub 2003/10/21).PubMedCrossRef
20.
Matsuguma H, Nakahara R, Igarashi S, Ishikawa Y, Suzuki H, Miyazawa N, et al. Pathologic stage I non-small cell lung cancer with high levels of preoperative serum carcinoembryonic antigen: clinicopathologic characteristics and prognosis. J Thorac Cardiovasc Surg. 2008;135:44–9. (Epub 2008/01/09).PubMedCrossRef
21.
Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, et al. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma. Ann Thorac Surg. 2004;78:1004–9. (discussion 9–10. Epub 2004/09/01).PubMedCrossRef
22.
Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31:992–1001. (Epub 2013/02/13).PubMedCrossRef
23.
Nakamura H, Saji H, Marushima H, Kimura H, Koizumi H, Takagi M. Associations between serum carcinoembryonic antigen levels and adenocarcinoma subtypes of the lung. Cancer Treat Commun. 2016;3:31–5.CrossRef
24.
Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76:138–43. (Epub 2011/12/14).PubMedCrossRef
25.
Wang XB, Li J, Han Y. Prognostic significance of preoperative serum carcinoembryonic antigen in non-small cell lung cancer: a meta-analysis. Tumour Biol. 2014;35:10105–10. (Epub 2014/07/16).PubMedCrossRef
26.
Zaleska M, Szturmowicz M, Zych J, Roszkowska-Sliz B, Demkow U, Langfort R, et al. Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival. Pneumonol Alergol Pol. 2010;78:14–20. (Epub 2010/02/18. Podwyzszone surowicze stezenie NSE w nieoperacyjnym niedrobnokomowym raku ptuca jest zwiazane z lepsza odpowiedzia na leczenie, ale z gorszym rokowaniem).PubMed
27.
Okada M, Sakamoto T, Nishio W, Uchino K, Tsubota N. Characteristics and prognosis of patients after resection of nonsmall cell lung carcinoma measuring 2 cm or less in greatest dimension. Cancer. 2003;98:535–41. (Epub 2003/07/25).PubMedCrossRef
28.
Rubins JB, Dunitz J, Rubins HB, Maddaus MA, Niewoehner DE. Serum carcinoembryonic antigen as an adjunct to preoperative staging of lung cancer. J Thorac Cardiovasc Surg. 1998;116:412–6. (Epub 1998/09/10).PubMedCrossRef
29.
Matsuoka K, Sumitomo S, Nakashima N, Nakajima D, Misaki N. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Eur J Cardiothorac Surg. 2007;32:435–9. (Epub 2007/07/06).PubMedCrossRef
30.
Hotta K, Segawa Y, Takigawa N, Kishino D, Saeki H, Nakata M, et al. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer. Anticancer Res. 2000;20:2177–80. (Epub 2000/08/06).PubMed
31.
Icard P, Regnard JF, Essomba A, Panebianco V, Magdeleinat P, Levasseur P. Preoperative carcinoembryonic antigen level as a prognostic indicator in resected primary lung cancer. Ann Thorac Surg. 1994;58:811–4. (Epub 1994/09/01).PubMedCrossRef
32.
Muley T, Dienemann H, Ebert W. CYFRA 21–1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Res. 2004;24:1953–6. (Epub 2004/07/28).PubMed
33.
Nisman B, Amir G, Lafair J, Heching N, Lyass O, Peretz T, et al. Prognostic value of CYFRA 21–1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res. 1999;19:3549–52. (Epub 2000/01/12).PubMed
34.
Tomita M, Matsuzaki Y, Edagawa M, Shimizu T, Hara M, Onitsuka T. Prognostic significance of preoperative serum carcinoembryonic antigen level in lung adenocarcinoma but not squamous cell carcinoma. Ann Thorac Cardiovasc Surg. 2004;10:76–80. (Epub 2004/06/24).PubMed
35.
Iwasaki A, Shirakusa T, Yoshinaga Y, Enatsu S, Yamamoto M. Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor. Eur J Cardiothorac Surg. 2004;26:488–93. (Epub 2004/08/11).PubMedCrossRef
36.
Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21–1 in non-small cell lung cancer. Anticancer Res. 2010;30:3099–102. (Epub 2010/08/05).PubMed
37.
Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T. Serum carcinoembryonic antigen level in non-small-cell lung cancer patients with preoperative normal serum level. Gen. Thorac Cardiovasc Surg. 2009;57:303–6. (Epub 2009/06/18).CrossRef
38.
Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, Nishiwaki Y. The prognosis of surgically resected N2 non-small cell lung cancer: the importance of clinical N status. J Thorac Cardiovasc Surg. 1999;118:145–53. (Epub 1999/06/29).PubMedCrossRef
39.
Arrieta O, Saavedra-Perez D, Kuri R, Aviles-Salas A, Martinez L, Mendoza-Posada D, et al. Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. BMC Cancer. 2009;9:119. (Epub 2009/04/24).PubMedPubMedCentralCrossRef
40.
Ford CH, Stokes HJ, Newman CE. Carcinoembryonic antigen and prognosis after radical surgery for lung cancer: immunocytochemical localization and serum levels. Br J Cancer. 1981;44:145–53. (Epub 1981/08/01).PubMedPubMedCentralCrossRef
41.
Sawabata N, Ohta M, Takeda S, Hirano H, Okumura Y, Asada H, et al. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. Ann Thorac Surg. 2002;74:174–9. (Epub 2002/07/18).PubMedCrossRef
42.
Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21–1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem. 2002;48:1931–7. (Epub 2002/10/31).PubMed
43.
Nisman B, Lafair J, Heching N, Lyass O, Baras M, Peretz T, et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21–1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer. 1998;82:1850–9. (Epub 1998/05/20).PubMedCrossRef
44.
Blankenburg F, Hatz R, Nagel D, Ankerst D, Reinmiedl J, Gruber C, et al. Preoperative CYFRA 21–1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score. Tumour Biol. 2008;29:272–7. (Epub 2008/09/11).PubMedCrossRef
45.
Buccheri G, Ferrigno D, Vola F. Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancer. Lung Cancer. 1993;10:21–33. (Epub 1993/10/01).PubMedCrossRef
46.
Hatzakis KD, Froudarakis ME, Bouros D, Tzanakis N, Karkavitsas N, Siafakas NM. Prognostic value of serum tumor markers in patients with lung cancer. Respiration. 2002;69:25–9. (Epub 2002/02/15).PubMedCrossRef
47.
Reinmuth N, Brandt B, Semik M, Kunze WP, Achatzy R, Scheld HH, et al. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer. 2002;36:265–70. (Epub 2002/05/16).PubMedCrossRef
48.
Kobayashi N, Toyooka S, Soh J, Ichimura K, Yanai H, Suehisa H, et al. Risk factors for recurrence and unfavorable prognosis in patients with stage I non-small cell lung cancer and a tumor diameter of 20 mm or less. J Thorac Oncol. 2007;2:808–12. (Epub 2007/09/07).PubMedCrossRef
49.
Schneider J, Philipp M, Velcovsky HG, Morr H, Katz N. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21–1) in patients with lung cancer in comparison to other lung diseases. Anticancer Res. 2003;23:885–93. (Epub 2003/06/25).PubMed
50.
Oremek GM, Sauer-Eppel H, Bruzdziak TH. Value of tumour and inflammatory markers in lung cancer. Anticancer Res. 2007;27:1911–5. (Epub 2007/07/26).PubMed
51.
Tomita M, Shimizu T, Ayabe T, Onitsuka T. Maximum SUV on positron emission tomography and serum CEA level as prognostic factors after curative resection for non-small cell lung cancer. Asia Pac J Clin Oncol. 2012;8:244–7. (Epub 2012/08/18).PubMedCrossRef
52.
Fukai R, Sakao Y, Sakuraba M, Oh S, Shiomi K, Sonobe S, et al. The prognostic value of carcinoembryonic antigen in T1N1M0 and T2N1M0 non-small cell carcinoma of the lung. Eur J Cardiothorac Surg. 2007;32:440–4. (Epub 2007/07/24).PubMedCrossRef
53.
Hsu WH, Huang CS, Hsu HS, Huang WJ, Lee HC, Huang BS, et al. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer. Ann Thorac Surg. 2007;83:419–24. (Epub 2007/01/30).PubMedCrossRef
54.
Tomita M, Matsuzaki Y, Shimizu T, Hara M, Ayabe T, Onitsuka T. Relationship between serum carcinoembryonic antigen level and T status in non-small cell lung cancer. Anticancer Res. 2006;26:3845–8. (Epub 2006/11/11).PubMed
55.
Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg. 2004;78:216–21. (Epub 2004/06/30).PubMedCrossRef
56.
Niizeki H, Morikawa T, Okushiba S, Kondo S, Katoh H. Survival and prognostic factors in resected cN2-pN0 non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 2004;10:9–13. (Epub 2004/03/11).PubMed
57.
Hanagiri T, Sugaya M, Takenaka M, Oka S, Baba T, Shigematsu Y, et al. Preoperative CYFRA 21–1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer. 2011;74:112–7. (Epub 2011/03/15).PubMedCrossRef
58.
Tsuchiya T, Akamine S, Muraoka M, Kamohara R, Tsuji K, Urabe S, et al. Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer. 2007;56:341–8. (Epub 2007/03/14).PubMedCrossRef
59.
Graziano SL, Tatum AH, Newman NB, Oler A, Kohman LJ, Veit LJ, et al. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer. Cancer Res. 1994;54:2908–13. (Epub 1994/06/01).PubMed
60.
Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol. 2002;20:2197–207. (Epub 2002/04/17).PubMedCrossRef
61.
Duxbury MS, Matros E, Ito H, Zinner MJ, Ashley SW, Whang EE. Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Ann Surg. 2004;240:667–74. (discussion 75–6. Epub 2004/09/24).PubMedPubMedCentral
62.
Staff C, Magnusson CG, Hojjat-Farsangi M, Mosolits S, Liljefors M, Frodin JE, et al. Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein. J Clin Immunol. 2012;32:855–65. (Epub 2012/03/03).
63.
Molina-Pinelo S, Gutierrez G, Pastor MD, Hergueta M, Moreno-Bueno G, Garcia-Carbonero R, et al. MicroRNA-dependent regulation of transcription in non-small cell lung cancer. PloS One. 2014;9:e90524. (Epub 2014/03/15).PubMedPubMedCentralCrossRef
64.
Aurisicchio L, Roscilli G, Marra E, Luberto L, Mancini R, La Monica N, et al. Superior Immunologic and Therapeutic Efficacy of a Xenogeneic Genetic Cancer Vaccine Targeting Carcinoembryonic Human Antigen. Hum Gene Ther. 2015;26:386–98. (Epub 2015/04/15).PubMedPubMedCentralCrossRef
65.
Hong KP, Shin MH, Yoon S, Ji GY, Moon YR, Lee OJ, et al. Therapeutic effect of anti CEACAM6 monoclonal antibody against lung adenocarcinoma by enhancing anoikis sensitivity. Biomaterials. 2015;67:32–41. (Epub 2015/07/24).PubMedCrossRef
66.
McCann KJ, Mander A, Cazaly A, Chudley L, Stasakova J, Thirdborough SM, et al. Targeting carcinoembryonic antigen with DNA vaccination: on-target adverse events link with immunological and clinical outcomes. Clin Cancer Res. 2016;22:4827–36. (Epub 2016/04/20).
67.
68.
Lurie BB, Loewenstein MS, Zamcheck N. Elevated carcinoembryonic antigen levels and biliary tract obstruction. JAMA. 1975;233:326–30. (Epub 1975/07/28).PubMedCrossRef
69.
Amino N, Kuro R, Yabu Y, Takai SI, Kawashima M, Morimoto S, et al. Elevated levels of circulating carcinoembryonic antigen in hypothyroidism. J Clin Endocrinol Metab. 1981;52:457–62. (Epub 1981/03/01).PubMedCrossRef
70.
Witherspoon LR, Shuler SE, Alyea K, Husserl FE. Carcinoembryonic antigen: assay following heat compared with perchloric acid extraction in patients with colon cancer, non-neoplastic gastrointestinal diseases, or chronic renal failure. J Nucl Med. 1983;24:916–21. (Epub 1983/10/01).PubMed
71.
Ruibal Morell A. CEA serum levels in non-neoplastic disease. Int J Biol Markers. 1992;7:160–6. (Epub 1992/07/01).PubMed
72.
Nomura F, Koyama A, Ishijima M, Takano S, Narita M, Nakai T. Serum levels of five tumor markers for lung cancer in patients with chronic renal failure. Oncol Rep. 1998;5:389–92. (Epub 1998/04/18).PubMed
73.
Bulut I, Arbak P, Coskun A, Balbay O, Annakkaya AN, Yavuz O, et al. Comparison of serum CA 19.9, CA 125 and CEA levels with severity of chronic obstructive pulmonary disease. Med Princ Pract. 2009;18:289–93. (Epub 2009/06/06).PubMedCrossRef
74.
Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21–1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 1993;53:61–6. (Epub 1993/01/01).PubMed
75.
Bodenmuller H, Ofenloch-Hahnle B, Lane EB, Dessauer A, Bottger V, Donie F. Lung cancer-associated keratin 19 fragments: development and biochemical characterisation of the new serum assay Enzymun-Test CYFRA 21–1. Int J Biol Markers. 1994;9:75–81. (Epub 1994/04/01).PubMed
76.
Lamy PJ, Fina F, Bascoul-Mollevi C, Laberenne AC, Martin PM, Ouafik L, et al. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Res. 2011;13:R15. (Epub 2011/02/04).PubMedPubMedCentralCrossRef
77.
Fuchs E, Weber K. Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem. 1994;63:345–82. (Epub 1994/01/01).PubMedCrossRef
78.
Coulombe PA, Omary MB. ‘Hard’ and ‘soft’ principles defining the structure, function and regulation of keratin intermediate filaments. Curr Opin Cell Biol. 2002;14:110–22. (Epub 2002/01/17).PubMedCrossRef
79.
Bader BL, Magin TM, Hatzfeld M, Franke WW. Amino acid sequence and gene organization of cytokeratin no. 19, an exceptional tail-less intermediate filament protein. EMBO J. 1986;5:1865–75. (Epub 1986/08/01).PubMedPubMedCentral
80.
Omary MB, Ku NO, Strnad P, Hanada S. Toward unraveling the complexity of simple epithelial keratins in human disease. J Clin Invest. 2009;119:1794–805. (Epub 2009/07/10).PubMedPubMedCentralCrossRef
81.
Bonfrer JM, Gaarenstroom KN, Kenter GG, Korse CM, Hart AA, Gallee MP, et al. Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21–1 in cervical cancer. Gynecol Oncol. 1994;55:371–5. (Epub 1994/12/01).PubMedCrossRef
82.
Narita T, Funahashi H, Imai T, Takagi H, Kannagi R. Cytosol and serum concentration of cytokeratin subunit-19 fragment (cyfra-21-1) in breast-cancer. Oncology Rep. 1994;1:747–50. (Epub 1994/07/01).
83.
Nakata B, Chung YS, Kato Y, Ogawa M, Ogawa Y, Inui A, et al. Clinical significance of serum CYFRA 21–1 in gastric cancer. Br J Cancer. 1996;73:1529–32. (Epub 1996/06/01).PubMedPubMedCentralCrossRef
84.
Uenishi T, Kubo S, Hirohashi K, Tanaka H, Shuto T, Yamamoto T, et al. Cytokeratin-19 fragments in serum (CYFRA 21–1) as a marker in primary liver cancer. Br J Cancer. 2003;88:1894–9. (Epub 2003/06/12).PubMedPubMedCentralCrossRef
85.
Wild N, Andres H, Rollinger W, Krause F, Dilba P, Tacke M, et al. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res. 2010;16:6111–21. (Epub 2010/08/28).PubMedCrossRef
86.
Jung M, Kim SH, Lee YJ, Hong S, Kang YA, Kim SK, et al. Prognostic and predictive value of CEA and CYFRA 21–1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Exp Ther Med. 2011;2:685–93. (Epub 2011/07/01).PubMedPubMedCentral
87.
Tanaka K, Hata A, Kaji R, Fujita S, Otoshi T, Fujimoto D, et al. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation. J Thorac Oncol. 2013;8:892–8. (Epub 2013/04/18).PubMedCrossRef
88.
Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, et al. Predictive role of CEA and CYFRA 21–1 in patients with advanced-stage NSCLC treated with erlotinib. Anticancer Res. 2014;34:3205–10. (Epub 2014/06/13).PubMed
89.
Pujol JL, Quantin X, Jacot W, Boher JM, Grenier J, Lamy PJ. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer. 2003;39:131–8. (Epub 2003/02/13).PubMedCrossRef
90.
Holdenrieder S, von Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, et al. Nucleosomes, ProGRP, NSE, CYFRA 21–1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res. 2008;14:7813–21. (Epub 2008/12/03).PubMedCrossRef
91.
Pujol JL, Molinier O, Ebert W, Daures JP, Barlesi F, Buccheri G, et al. CYFRA 21–1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer. 2004;90:2097–105. (Epub 2004/05/20).PubMedPubMedCentral
92.
Pujol JL, Boher JM, Grenier J, Quantin X. Cyfra 21–1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer. 2001;31:221–31. (Epub 2001/02/13).PubMedCrossRef
93.
Ebert W, Hoppe M, Muley T, Drings P. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21–1, TPA- TP CEA, and NSE. Anticancer Res. 1997;17:2875–8. (Epub 1997/07/01).PubMed
94.
Hamzaoui A, Thomas P, Castelnau O, Roux N, Roux F, Kleisbauer JP. Usefulness of longitudinal evaluation of Cyfra 21–1 variations in advanced lung cancer monitoring. Lung Cancer. 1997;16:191–202. (Epub 1997/03/01).PubMedCrossRef
95.
Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol. 1995;13:1221–30. (Epub 1995/05/01).PubMedCrossRef
96.
Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, et al. Cyfra 21–1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest. 1995;108:163–9. (Epub 1995/07/01).PubMedCrossRef
97.
Moro D, Villemain D, Vuillez JP, Delord CA, Brambilla C. CEA, CYFRA21-1 and SCC in non-small cell lung cancer. Lung Cancer. 1995;13:169–76. (Epub 1995/10/01).PubMedCrossRef
98.
Szturmowicz M, Sakowicz A, Rudzinski P, Zych J, Wiatr E, Zaleska J, et al. The clinical value of Cyfra 21–1 estimation for lung cancer patients. Int J Biol Markers. 1996;11:172–7. (Epub 1996/07/01).PubMed
99.
Brechot JM, Chevret S, Nataf J, Le Gall C, Fretault J, Rochemaure J, et al. Diagnostic and prognostic value of Cyfra 21–1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer. 1997;33:385–91. (Epub 1997/03/01).PubMedCrossRef
100.
Xu Y, Xu L, Qiu M, Wang J, Zhou Q, Yin R. Prognostic value of serum cytokeratin 19 fragments (Cyfra 21–1) in patients with non-small cell lung cancer. Sci Rep. 2015;5:9444. (Epub 2015/04/23).PubMedPubMedCentralCrossRef
101.
Lin XF, Wang XD, Sun DQ, Li Z, Bai Y. High Serum CEA and CYFRA21-1 Levels after a Two-Cycle Adjuvant Chemotherapy for NSCLC. Possible Poor Prognostic Factors. Cancer Biol Med. 2012;9:270–3. (Epub 2013/05/22).PubMedPubMedCentral
102.
Park SY, Lee JG, Kim J, Park Y, Lee SK, Bae MK, et al. Preoperative serum CYFRA 21–1 level as a prognostic factor in surgically treated adenocarcinoma of lung. Lung Cancer. 2013;79:156–60. (Epub 2012/12/05).PubMedCrossRef
103.
Trape J, Montesinos J, Catot S, Buxo J, Franquesa J, Sala M, et al. A prognostic score based on clinical factors and biomarkers for advanced non-small cell lung cancer. Int J Biol Markers. 2012;27:e257–e262. (Epub 2012/07/21).PubMedCrossRef
104.
Edelman MJ, Hodgson L, Rosenblatt PY, Christenson RH, Vokes EE, Wang X, et al. CYFRA 21–1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol. 2012;7:649–54. (Epub 2012/03/20).PubMedCrossRef
105.
Cedres S, Nunez I, Longo M, Martinez P, Checa E, Torrejon D, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2011;12:172–9. (Epub 2011/06/15).PubMedCrossRef
106.
Ma S, Shen L, Qian N, Chen K. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited. Cancer Biomark. 2011;10:155–62. (Epub 2011/01/01).PubMedCrossRef
107.
Jin B, Huang AM, Zhong RB, Han BH. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer. Chemotherapy. 2010;56:417–23. (Epub 2010/11/17).PubMedCrossRef
108.
Takahashi H, Kurishima K, Ishikawa H, Kagohashi K, Kawaguchi M, Satoh H. Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis. Anticancer Res. 2010;30:3833–7. (Epub 2010/10/15).PubMed
109.
De Petris L, Branden E, Herrmann R, Sanchez BC, Koyi H, Linderholm B, et al. Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer. Eur J Cancer. 2011;47:131–7. (Epub 2010/09/09).PubMedCrossRef
110.
Nisman B, Biran H, Ramu N, Heching N, Barak V, Peretz T. The diagnostic and prognostic value of ProGRP in lung cancer. Anticancer Res. 2009;29:4827–32. (Epub 2009/12/25).PubMed
111.
Chen F, Luo X, Zhang J, Lu Y, Luo R. Elevated serum levels of TPS and CYFRA 21–1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib. Med Oncol. 2010;27:950–7. (Epub 2009/10/16).PubMedCrossRef
112.
Chakra M, Pujol JL, Lamy PJ, Bozonnat MC, Quantin X, Jacot W, et al. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. J Thorac Oncol. 2008;3:1119–26. (Epub 2008/10/02).PubMedCrossRef
113.
Jacot W, Colinet B, Bertrand D, Lacombe S, Bozonnat MC, Daures JP, et al. Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients. Ann Oncol. 2008;19:1458–64. (Epub 2008/03/22).PubMedCrossRef
114.
Ishikawa N, Hattori N, Yokoyama A, Tanaka S, Nishino R, Yoshioka K, et al. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Cancer. 2008;122:2612–20. (Epub 2008/03/08).PubMedCrossRef
115.
Nisman B, Biran H, Heching N, Barak V, Ramu N, Nemirovsky I, et al. Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival. Br J Cancer. 2008;98:7779. (Epub 2007/12/19).CrossRef
116.
Suzuki H, Ishikawa S, Satoh H, Ishikawa H, Sakai M, Yamamoto T, et al. Preoperative CYFRA 21–1 levels as a prognostic factor in c-stage I non-small cell lung cancer. Eur J Cardiothorac Surg. 2007;32:648–52. (Epub 2007/08/21).PubMedCrossRef
117.
Mizuguchi S, Nishiyama N, Iwata T, Nishida T, Izumi N, Tsukioka T, et al. Clinical value of serum cytokeratin 19 fragment and sialyl-Lewis x in non-small cell lung cancer. Ann Thorac Surg. 2007;83:216–21. (Epub 2006/12/23).PubMedCrossRef
118.
Barlesi F, Tchouhadjian C, Doddoli C, Torre JP, Astoul P, Kleisbauer JP. CYFRA 21–1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy. Br J Cancer. 2005;92:13–4. (Epub 2004/12/15).PubMedCrossRef
119.
Barlesi F, Gimenez C, Torre JP, Doddoli C, Mancini J, Greillier L, et al. Prognostic value of combination of Cyfra 21–1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med. 2004;98:357–62. (Epub 2004/04/15).PubMedCrossRef
120.
Trape J, Buxo J, Perez de Olaguer J, Vidal C. Tumor markers as prognostic factors in treated non-small cell lung cancer. Anticancer Res. 2003;23:4277–81. (Epub 2003/12/12).PubMed
121.
Ono A, Takahashi T, Mori K, Akamatsu H, Shukuya T, Taira T, et al. Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study. BMC Cancer. 2013;13:354. (Epub 2013/07/25).PubMedPubMedCentralCrossRef
122.
Szturmowicz M, Rudzinski P, Kacprzak A, Langfort R, Bestry I, Broniarek-Samson B, et al. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21–1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer. Pneumonol Alergol Pol. 2014;82:422–9. (Epub 2014/08/19).PubMedCrossRef
123.
Nakahama H, Tanaka Y, Fujita Y, Fujii M, Sugita M. CYFRA 21–1 and ProGRP, tumor markers of lung cancer, are elevated in chronic renal failure patients. Respirology. 1998;3:207–10. (Epub 1998/10/10).PubMedCrossRef
124.
Tempfer C, Hefler L, Heinzl H, Loesch A, Gitsch G, Rumpold H, et al. CYFRA 21–1 serum levels in women with adnexal masses and inflammatory diseases. Br J Cancer. 1998;78:1108–12. (Epub 1998/10/29).PubMedPubMedCentralCrossRef
125.
Xu RH, Liao CZ, Luo Y, Xu WL, Li K, Chen JX, et al. Optimal cut-off values for CYFRA 21–1 expression in NSCLC patients depend on the presence of benign pulmonary diseases. Clin Chim Acta. 2015;440:188–92. (Epub 2014/10/12).PubMedCrossRef
126.
Bjorklund B. Serological analysis of human cancer antigen. Proceedings of the VI th International Congress of Microbiology Rome, Italy. 1953.
127.
Luning B, Nilsson U. Sequence homology between tissue polypeptide antigen (TPA) and intermediate filament (IF) proteins. Acta Chemica Scandinavia В. 1983; 37:731–733. (Epub 1983/01/01).
128.
Nathrath WB, Heidenkummer P, Bjorklund V, Bjorklund B. Distribution of tissue polypeptide antigen (TPA) in normal human tissues: Immunohistochemical study on unfixed, methanol-, ethanol-, and formalin-fixed tissues. J Histochem Cytochem. 1985;33:99–109. (Epub 1985/02/01).PubMedCrossRef
129.
Weber K, Osborn M, Moll R, Wiklund B, Luning B. Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a human tumor marker. EMBO J. 1984;3:2707–14. (Epub 1984/11/01).PubMedPubMedCentral
130.
Nemoto T, Constantine R, Chu TM. Human tissue polypeptide antigen in breast cancer. J Natl Cancer Inst. 1979;63:1347–50. (Epub 1979/12/01).PubMed
131.
Uehara Y, Kojima O, Ikeda E, Majima T, Nishioka B, Fujita Y, et al. Detection of gastric cancer by a combination of tissue polypeptide antigen (TPA), lipid-bound sialic acid (LBSA) and carcinoembryonic antigen (CEA). Gastroenterol Jpn. 1984;19:424–9. (Epub 1984/10/01).PubMed
132.
Martino E, Bambini G, Aghini-Lombardi F, Motz E, Pacini F, Lari R, et al. Serum tissue polypeptide antigen (TPA) in thyroid cancer. J Endocrinol Invest. 1984;7:249–52. (Epub 1984/06/01).PubMedCrossRef
133.
Adolphs HD, Oehr P. Significance of plasma tissue polypeptide antigen determination for diagnosis and follow-up of urothelial bladder cancer. Urol Res. 1984;12:125–8. (Epub 1984/01/01).PubMed
134.
Rasmuson T, Bjork GR, Damber L, Holm SE, Jacobsson L, Jeppsson A, et al. Tumor markers in colorectal carcinoma. An evaluation of carcinoembryonic antigen, tissue polypeptide antigen, placental alkaline phosphatase and pseudouridine. Acta Radiol. Oncol. 1984;23:27–32. (Epub 1984/01/01).
135.
Rodenburg CJ, De Maaker GA, Trimbos JB, Moolenaar AJ, Van Oosterom AT. CA 125 and TPA as markers in ovarian carcinoma. Neth J Med. 1985;28:536–40. (Epub 1985/01/01).PubMed
136.
Lewenhaupt A, Ekman P, Eneroth P, Eriksson A, Nordstrom L. Serum levels of prostatic acid phosphatase (PAP), tissue polypeptide antigen (TPA), CA-50, neopterine and of osteocalcin in patients with prostatic carcinoma. Scand J Clin Lab Invest Suppl. 1985;179:75–80. (Epub 1985/01/01).PubMed
137.
Salvati F, Antilli A, Cruciani AR, Pau F, Flore F, Munno R, et al. Plasma carcinoembryonic antigen and tissue polypeptide antigen levels in lung cancer: correlation with cell types and stage. Cancer Detect Prev. 1985;8:111–4. (Epub 1985/01/01).PubMed
138.
Buccheri GF, Ferrigno D, Sartoris AM, Violante B, Vola F, Curcio A. Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19–9. Cancer. 1987;60:42–50. (Epub 1987/07/01).PubMedCrossRef
139.
Mizushima Y, Hirata H, Izumi S, Hoshino K, Konishi K, Morikage T, et al. Clinical significance of the number of positive tumor markers in assisting the diagnosis of lung cancer with multiple tumor marker assay. the International Society for Cellular. 1990;47:43–8. (Epub 1990/01/01).
140.
Plebani M, Basso D, Navaglia F, De Paoli M, Tommasini A, Cipriani A. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer. 1995;72:170–3. (Epub 1995/07/01).PubMedPubMedCentralCrossRef
141.
Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. Science. 1981;212:53–5. (Epub 1981/04/03).PubMedCrossRef
142.
Jalanko H, Kuusela P, Roberts P, Sipponen P, Haglund CA, Makela O. Comparison of a new tumor marker, CA 19–9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol. 1984;37:218–22. (Epub 1984/02/01).PubMedPubMedCentralCrossRef
143.
Magnani JL. The discovery, biology, and drug development of sialyl Lea and sialyl Lex. Arch Biochem Biophys. 2004;426:122–31. (Epub 2004/05/26).PubMedCrossRef
144.
Dietel M, Arps H, Klapdor R, Muller-Hagen S, Sieck M, Hoffmann L. Antigen detection by the monoclonal antibodies CA 19–9 and CA 125 in normal and tumor tissue and patients’ sera. J Cancer Res Clin Oncol. 1986;111:257–65. (Epub 1986/01/01).PubMedCrossRef
145.
Magnani JL, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19–9 in the sera of patients as a mucin. Cancer Res. 1983;43:5489–92. (Epub 1983/11/01).PubMed
146.
Soejima M, Koda Y. Molecular mechanisms of Lewis antigen expression. Leg Med (Tokyo). 2005;7:266–9. (Epub 2005/06/11).CrossRef
147.
Safi F, Roscher R, Beger HG. The clinical relevance of the tumor marker CA 19–9 in the diagnosing and monitoring of pancreatic carcinoma. Bull Cancer. 1990;77:83–91. (Epub 1990/01/01).PubMed
148.
Huang Z, Liu F. Diagnostic value of serum carbohydrate antigen 19–9 in pancreatic cancer: a meta-analysis. Tumour Biol. 2014;35:7459–65. (Epub 2014/05/03).PubMedCrossRef
149.
Niklinski J, Furman M, Laudanski J, Kozlowski M. Prognostic value of pretreatment CEA, SCC-Ag and CA 19–9 levels in sera of patients with non-small cell lung cancer. Eur J Cancer. 1992;1:401–6. (Epub 1992/10/01).CrossRef
150.
Kawai T, Suzuki M, Kase K, Ozeki Y. Expression of carbohydrate antigens in human pulmonary adenocarcinoma. Cancer. 1993;72:1581–7. (Epub 1993/09/01).PubMedCrossRef
151.
Toumbis M, Rasidakis A, Passalidou E, Dimitroulis J, Gaga M, Alchanatis M, et al. Diagnostic usefulness of 5 tumor-markers in patients with primary lung-cancer. Oncol Rep. 1995;2:1135–40. (Epub 1995/11/01).PubMed
152.
Tsumatori G, Ozeki Y, Takagi K, Ogata T, Tanaka S. Relation between the serum E-selectin level and the survival rate of patients with resected non-small cell lung cancers. Jpn J Cancer Res. 1999;90:301–7. (Epub 1999/06/08).PubMedCrossRef
153.
Yokoyama A, Kohno N, Kondo K, Ueda S, Hirasawa Y, Watanabe K, et al. Comparative evaluation of sialylated carbohydrate antigens, KL-6, CA19-9 and SLX as serum markers for interstitial pneumonia. Respirology. 1998;3:199–202. (Epub 1998/10/10).PubMedCrossRef
154.
Bertino G, Ardiri AM, Boemi P, Bruno CM, Valenti M, Mazzarino MC, et al. Meaning of elevated CA 19–9 serum levels in chronic hepatitis and HCV-related cirrhosis. Minerva Gastroenterol Dietol. 2007;53:305–9. (Epub 2007/11/29).PubMed
155.
Malesci A, Tommasini MA, Bonato C, Bocchia P, Bersani M, Zerbi A, et al. Determination of CA 19–9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology. 1987;92:60–7. (Epub 1987/01/01).PubMedCrossRef
156.
Ambiru S, Nakamura S, Fukasawa M, Mishima O, Kuwahara T, Takeshi A. Intralobar pulmonary sequestration associated with marked elevation of serum carbohydrate antigen 19–9. Ann Thorac Surg. 2009;88:2010–1. (Epub 2009/11/26).PubMedCrossRef
157.
Yango J, Pieters T, Coche E, Lambert M. [Increased serum CA 19.9 in bronchiectasis]. Rev Mal Respir. 2008;25:78–81. (Epub 2008/02/22. Elevation du CA 19.9 serique et bronchectasies).
158.
Rauvala H. Isolation and partial characterization of human kidney gangliosides. Biochim Biophys Acta. 1976;424:284–95. (Epub 1976/02/23).PubMedCrossRef
159.
Imada T, Rino Y, Takahashi M, Hatori S, Shiozawa M, Tanaka J, et al. Expression of CA19-9, SLX, STN and CEA in relatively early gastric carcinoma. Oncology Rep. 1997;4:899–904. (Epub 1997/09/01).
160.
Liang JX, Liang Y, Gao W. Clinicopathological and prognostic significance of sialyl Lewis X overexpression in patients with cancer: a meta-analysis. Onco Targets Ther. 2016;9:3113–25. (Epub 2016/06/17).PubMedPubMedCentral
161.
Komatsu H, Mizuguchi S, Izumi N, Chung K, Hanada S, Inoue H, et al. Sialyl Lewis X as a predictor of skip N2 metastasis in clinical stage IA non-small cell lung cancer. World J Surg Oncol. 2013;11:309. (Epub 2013/12/10).PubMedPubMedCentralCrossRef
162.
Satoh H, Ishikawa H, Kamma H, Yamashita YT, Takahashi H, Ohtsuka M, et al. Elevated serum sialyl Lewis X-i antigen levels in non-small cell lung cancer with lung metastasis. Respiration. 1998;65:295–8. (Epub 1998/09/08).PubMedCrossRef
163.
Sakai N, Okada Y, Tsuji T. Increased serum levels of the carrier molecules of the carbohydrate antigen sialyl Lewis X in liver diseases. Acta Med Okayama. 1997;51:79–85. (Epub 1997/04/01).PubMed
164.
Mukae H, Hirota M, Kohno S, Komori K, Fukushima K, Hiratani K, et al. Elevation of tumor-associated carbohydrate antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis. 1993;148:744–51. (Epub 1993/09/01).PubMedCrossRef
165.
Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331–7. (Epub 1981/11/01).PubMedPubMedCentralCrossRef
166.
Elola MT, Chiesa ME, Alberti AF, Mordoh J, Fink NE. Galectin-1 receptors in different cell types. J Biomed Sci. 2005;12:13–29. (Epub 2005/05/03).PubMedCrossRef
167.
Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305:2295–2303. (168).CrossRef
168.
Yu D, Du K, Liu T, Chen G. Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients. Int J Mol Sci. 2013;14:11145–56. (Epub 2013/05/29).PubMedPubMedCentralCrossRef
169.
Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer. 1977;40:1621–8. (Epub 1977/10/01).PubMedCrossRef
170.
Alajaji JT, Courey MH, Azar HA, Ries KM, Skipper PM, Endicott JN. Plasma levels of a squamous cell carcinoma-associated antigen in athymic nude mice bearing human squamous cell carcinoma xenografts of oral origin. With preliminary clinical data. Cancer. 1988;62:2291–6. (Epub 1988/12/01).PubMedCrossRef
171.
Suminami Y, Kishi F, Sekiguchi K, Kato H. Squamous cell carcinoma antigen is a new member of the serine protease inhibitors. Biochem Biophys Res Commun. 1991;181:51–8. (Epub 1991/11/27).PubMedCrossRef
172.
Schneider SS, Schick C, Fish KE, Miller E, Pena JC, Treter SD, et al. A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc Natl Acad Sci U S A. 1995;92:3147–51. (Epub 1995/04/11).PubMedPubMedCentralCrossRef
173.
Kuwano A, Kondo I, Kishi F, Suminami Y, Kato H. Assignment of the squamous cell carcinoma antigen locus (SCC) to 18q21 by in situ hybridization. Genomics. 1995;30:626. (Epub 1995/12/10).PubMedCrossRef
174.
Nawata S, Tsunaga N, Numa F, Tanaka T, Nakamura K, Kato H. Serine protease inhibitor activity of recombinant squamous cell carcinoma antigen towards chymotrypsin, as demonstrated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Electrophoresis. 1995;16:1027–30. (Epub 1995/06/01).PubMedCrossRef
175.
Nawata S, Nakamura K, Tanaka T, Numa F, Suminami Y, Tsunaga N, et al. Electrophoretic analysis of the “cross-class” interaction between novel inhibitory serpin, squamous cell carcinoma antigen-1 and cysteine proteinases. Electrophoresis. 1997;18:784–9. (Epub 1997/05/01).PubMedCrossRef
176.
Schick C, Kamachi Y, Bartuski AJ, Cataltepe S, Schechter NM, Pemberton PA, et al. Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase. J Biol Chem. 1997;272:1849–55. (Epub 1997/01/17).PubMedCrossRef
177.
Schick C, Pemberton PA, Shi GP, Kamachi Y, Cataltepe S, Bartuski AJ, et al. Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: a kinetic analysis. BioChemistry. 1998;37:5258–66. (Epub 1998/05/16).PubMedCrossRef
178.
Murakami A, Yoshidomi K, Sugino N. Involvement of squamous cell carcinoma antigen in invasion and metastasis of squamous cell carcinoma of uterine cervix. In: Li X, editor. Squamous cell carcinoma. Shanghai: In Tech; 2012. pp. 153–60.
179.
Bhatavdekar JM, Ghosh N, Shukla MK, Balar DB, Bhaduri A, Karelia NH, et al. Prognostic value of squamous cell carcinoma antigen in patients with uterine cervical carcinoma. Tumori. 1988;74:221–5. (Epub 1988/04/30).PubMed
180.
Fuith LC, Daxenbichler G. Squamous cell carcinoma antigen in patients with cancer of the uterine cervix. Gynecol Obstet Invest. 1988;26:77–82. (Epub 1988/01/01).PubMedCrossRef
181.
Yamanaka N, Himi T, Harabuchi Y, Hoki K, Kataura A. Soluble immune complexes and squamous cell carcinoma-related antigens in patients with head and neck cancer. Cancer. 1988;62:1932–8. (Epub 1988/11/01).PubMedCrossRef
182.
Mino-Miyagawa N, Kimura Y, Hamamoto K. Tumor-antigen 4. Its immunohistochemical distribution and tissue and serum concentrations in squamous cell carcinoma of the lung and esophagus. Cancer. 1990;66:1505–12. (Epub 1990/10/01).PubMedCrossRef
183.
Castelli M, Salvati F, Cruciani A, Portalone L, Giannarelli D, Ferrini U. Comparative analysis of CEA and SCC serum markers with IAP in human lung cancer. Int J Biol Markers. 1989;4:45–50. (Epub 1989/01/01).PubMed
184.
Body JJ, Sculier JP, Raymakers N, Paesmans M, Ravez P, Libert P, et al. Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer. Cancer. 1990;65:1552–6. (Epub 1990/04/01).PubMedCrossRef
185.
Foa P, Fornier M, Miceli R, Seregni E, Santambrogio L, Nosotti M, et al. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res. 1999;19:3613–8. (Epub 2000/01/12).PubMed
186.
Foa P, Fornier M, Miceli R, Seregni E, Santambrogio L, Nosotti M, et al. Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer. Int J Biol Markers. 1999;14:92–8. (Epub 1999/07/10).PubMed
187.
Schneider J, Velcovsky HG, Morr H, Katz N, Neu K, Eigenbrodt E. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21–1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res. 2000;20:5053–8. (Epub 2001/05/01).PubMed
188.
Ando S, Kimura H, Iwai N, Shima M, Ando M, Kuriyama T. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Anticancer Res. 2001;21:3085–92. (Epub 2001/11/20).PubMed
189.
Molina R, Auge JM, Filella X, Vinolas N, Alicarte J, Domingo JM, et al. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21–1 and NSE in patients with lung cancer. Anticancer Res. 2005;25:1773–8. (Epub 2005/07/22).PubMed
190.
Gris JM, Xercavins J, Trillo L, Encabo G. Study of the squamous cell carcinoma (SCC) antigen in benign diseases. Med Clin. 1996;106:205–8. (scc en las enfermedades benignas).
191.
Sakito O, Kadota J, Kohno S, Itoh N, Takahara O, Hara K. Pulmonary infiltration with eosinophilia and increased serum levels of squamous cell carcinoma-related antigen and neuron specific enolase. Intern Med. 1994;33:550–3. (Epub 1994/09/01).PubMedCrossRef
192.
Watanabe Y, Yamaguchi Y, Komitsu N, Ohta S, Azuma Y, Izuhara K, et al. Elevation of serum squamous cell carcinoma antigen 2 in patients with psoriasis: associations with disease severity and response to the treatment. Br J Dermatol. 2016;174:1327–36. (Epub 2016/01/30).PubMedCrossRef
193.
Schmechel D, Marangos PJ, Brightman M. Neuron-specific enolase is a molecular marker for peripheral and central neuroendocrine cells. Nature. 1978;276:834–6.PubMedCrossRef
194.
Kirino T, Brightman MW, Oertel WH, Schmechel DE, Marangos PJ. Neuron-specific enolase as an index of neuronal regeneration and reinnervation. J Neurosci. 1983;3:915–23.PubMed
195.
Cheng F, Yuan Q, Yang J, Wang W, Liu H. The prognostic value of serum neuron-specific enolase in traumatic brain injury: systematic review and meta-analysis. PloS One. 2014;9:e106680. (Epub 2014/09/05).PubMedPubMedCentralCrossRef
196.
Isgro MA, Bottoni P, Scatena R. Neuron-specific enolase as a biomarker: Biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:125–43. (Epub 2015/11/05).PubMedCrossRef
197.
Pahlman S, Esscher T, Bergh J, Steinholtz L, Nou E, Nilsson K. Neuron-specific enolase as a marker for neuroblastoma and small-cell carcinoma of the lung. Tumour Biol. 1984;5:119–26. (Epub 1984/01/01).PubMed
198.
Carney DN, Marangos PJ, Ihde DC, Bunn PA Jr, Cohen MH, Minna JD, et al. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet. 1982;1:583–5. (Epub 1982/03/13).PubMedCrossRef
199.
Johnson DH, Marangos PJ, Forbes JT, Hainsworth JD, Van Welch R, Hande KR, et al. Potential utility of serum neuron-specific enolase levels in small cell carcinoma of the lung. Cancer Res. 1984;44:5409–14. (Epub 1984/11/01).PubMed
200.
Akoun GM, Scarna HM, Milleron BJ, Benichou MP, Herman DP. Serum neuron-specific enolase. A marker for disease extent and response to therapy for small-cell lung cancer. Chest. 1985;87:39–43. (Epub 1985/01/01).PubMedCrossRef
201.
Esscher T, Steinholtz L, Bergh J, Nou E, Nilsson K, Pahlman S. Neurone specific enolase: a useful diagnostic serum marker for small cell carcinoma of the lung. Thorax. 1985;40:85–90. (Epub 1985/02/01).PubMedPubMedCentralCrossRef
202.
Hirose T, Okuda K, Yamaoka T, Ishida K, Kusumoto S, Sugiyama T, et al. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer? Lung Cancer. 2011;71:224–8. (Epub 2010/06/12).PubMedCrossRef
203.
Huang Z, Xu D, Zhang F, Ying Y, Song L. Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer. Clin Transl Oncol. 2016;18:1019–25. (Epub 2016/02/18).
204.
Maeda T, Ueoka H, Tabata M, Kiura K, Shibayama T, Gemba K, et al. Prognostic factors in advanced non-small cell lung cancer: elevated serum levels of neuron specific enolase indicate poor prognosis. Jpn J Clin Oncol. 2000;30:534–41. (Epub 2001/02/24).PubMedCrossRef
205.
Satoh H, Ishikawa H, Kurishima K, Yamashita YT, Ohtsuka M, Sekizawa K. Cut-off levels of NSE to differentiate SCLC from NSCLC. Oncol Rep. 2002;9:581–3. (Epub 2002/04/17).PubMed
206.
Ferrigno D, Buccheri G, Giordano C. Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC). Lung Cancer. 2003;41:311–20. (Epub 2003/08/21).PubMedCrossRef
207.
Tiseo M, Ardizzoni A, Cafferata MA, Loprevite M, Chiaramondia M, Filiberti R, et al. Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer. Anticancer Res. 2008;28:507–13. (Epub 2008/04/04).PubMed
208.
Yan HJ, Tan Y, Gu W. Neuron specific enolase and prognosis of non-small cell lung cancer: a systematic review and meta-analysis. J BUON. 2014;19:153–6. (Epub 2014/03/25).PubMed
209.
Inomata M, Hayashi R, Yamamoto A, Tokui K, Taka C, Okazawa S, et al. Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib. Mol. Clin Oncol. 2015;3:802–6. (Epub 2015/07/15).
210.
Suh KJ, Keam B, Kim M, Park YS, Kim TM, Jeon YK, et al. Serum neuron-specific enolase levels predict the efficacy of first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations. Clin Lung Cancer. 2016; 17:245–252 e1. (Epub 2016/01/01).
211.
Kamata K, Uchida M, Takeuchi Y, Takahashi E, Sato N, Miyake Y, et al. Increased serum concentrations of pro-gastrin-releasing peptide in patients with renal dysfunction. Nephrol Dial Transplant. 1996;11:1267–70.PubMedCrossRef
212.
Dumesny C, Patel O, Lachal S, Giraud AS, Baldwin GS, Shulkes A. Synthesis, expression and biological activity of the prohormone for gastrine releasing peptide (proGRP). Endocrinology. 2006;147:502–9.PubMedCrossRef
213.
Cuttitta F, Fedorko J, Gu JA, Lebacq-Verheyden AM, Linnoila RI, Battey JF. Gastrin-releasing peptide gene-associated peptides are expressed in normal human fetal lung and small cell lung cancer: a novel peptide family found in man. J Clin Endocrinol Metab. 1988;67:576–83. (Epub 1988/09/01).PubMedCrossRef
214.
Yamaguchi K, Aoyagi K, Urakami K, Fukutani T, Maki N, Yamamoto S, et al. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement. Jpn J Cancer Res. 1995;86:698–705. (Epub 1995/07/01).PubMedCrossRef
215.
Lebacq-Verheyden AM, Bertness V, Kirsch I, Hollis GF, McBride OW, Battey J. Human gastrin-releasing peptide gene maps to chromosome band 18q21. Somat Cell Mol Genet. 1987;13:81–6. (Epub 1987/01/01).PubMedCrossRef
216.
Okusaka T, Eguchi K, Kasai T, Kurata T, Yamamoto N, Ohe Y, et al. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clin Cancer Res. 1997;3:123–7. (Epub 1997/01/01).PubMed
217.
Takada M, Kusunoki Y, Masuda N, Matui K, Yana T, Ushijima S, et al. Pro-gastrin-releasing peptide (31–98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. Br J Cancer. 1996;73:1227–32. (Epub 1996/05/01).PubMedPubMedCentralCrossRef
218.
Stieber P, Dienemann H, Schalhorn A, Schmitt UM, Reinmiedl J, Hofmann K, et al. Pro-gastrin-releasing peptide (ProGRP)–a useful marker in small cell lung carcinomas. Anticancer Res. 1999;19:2673–8. (Epub 1999/09/02).PubMed
219.
Shibayama T, Ueoka H, Nishii K, Kiura K, Tabata M, Miyatake K, et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer. 2001;32:61–9. (Epub 2001/04/03).PubMedCrossRef
220.
Wojcik E, Kulpa JK, Sas-Korczynska B, Korzeniowski S, Jakubowicz J. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Anticancer Res. 2008;28:3027–33. (Epub 2008/11/27).PubMed
221.
Molina R, Auge JM, Alicarte J, Filella X, Vinolas N, Ballesta AM. Pro-gastrin-releasing peptide in patients with benign and malignant diseases. Tumour Biol. 2004;25:56–61. (Epub 2004/06/12).PubMedCrossRef
222.
Nisman B, Heching N, Biran H, Barak V, Peretz T. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer. Tumour Biol. 2006;27:8–16. (Epub 2005/12/13).PubMedCrossRef
223.
Nordlund MS, Bjerner J, Warren DJ, Nustad K, Paus E. Progastrin-releasing peptide: stability in plasma/serum and upper reference limit. Tumour Biol. 2008;29:204–10. (Epub 2008/08/01).PubMedCrossRef
224.
Paone G, De Angelis G, Munno R, Pallotta G, Bigioni D, Saltini C, et al. Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1. Eur Respir J. 1995;8:1136–40. (Epub 1995/07/01).PubMedCrossRef
225.
Spiridonidis CH, Laufman LR, Stydnicki KA, Noltimier JW, Cho CC, Young DC, et al. Decline of posttreatment tumor marker levels after therapy of nonsmall cell lung cancer. A useful outcome predictor. Cancer. 1995;75:1586–93. (Epub 1995/04/01).PubMedCrossRef
226.
Paone G, De Angelis G, Portalone L, Greco S, Giosue S, Taglienti A, et al. Validation of an algorithm able to differentiate small-cell lung cancer (SCLC) from non-small-cell lung cancer (NSCLC) patients by means of a tumour marker panel: analysis of the errors. Br J Cancer. 1997;75:448–50. (Epub 1997/01/01).PubMedPubMedCentralCrossRef
227.
Li X, Asmitananda T, Gao L, Gai D, Song Z, Zhang Y, et al. Biomarkers in the lung cancer diagnosis: a clinical perspective. Neoplasma. 2012;59:500–7. (Epub 2012/06/07).PubMedCrossRef
228.
Yang DW, Zhang Y, Hong QY, Hu J, Li C, Pan BS, et al. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients. Cancer. 2015; 121(Suppl 17):3113–21. (Epub 2015/09/04).PubMedCrossRef
229.
Molina R, Marrades RM, Auge JM, Escudero JM, Vinolas N, Reguart N, et al. Assessment of a combined panel of six serum tumor markers for lung cancer. Am J Respir Crit Care Med. 2016;193:427–37. (Epub 2015/10/16).PubMedCrossRef
230.
Wang L, Wang D, Zheng G, Yang Y, Du L, Dong Z, et al. Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer. Int J Biol Markers. 2016;31:e80–e87. (Epub 2015/11/13).PubMed
Metadaten
Titel
History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer
verfasst von
Haruhiko Nakamura
Toshihide Nishimura
Publikationsdatum
22.02.2017
Verlag
Springer Japan
Erschienen in
Surgery Today / Ausgabe 9/2017
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-017-1477-y

Weitere Artikel der Ausgabe 9/2017

Surgery Today 9/2017 Zur Ausgabe

Original Article

A deep azygoesophageal recess may increase the risk of secondary spontaneous pneumothorax

Original Article

Effect of collagen vascular disease-associated interstitial lung disease on the outcomes of lung cancer surgery

Original Article

One-day nasogastric tube decompression after distal gastrectomy: a prospective randomized study

Original Article

Prevalence and clinicopathologic/molecular characteristics of mismatch repair-deficient colorectal cancer in the under-50-year-old Japanese population

Original Article

New macroscopic classification and back-flow thrombectomy for advanced hepatocellular carcinoma with portal vein tumor thrombus invading the contralateral second portal branch

Original Article

A comparison of the localization of rectal carcinomas according to the general rules of the Japanese classification of colorectal carcinoma (JCCRC) and Western guidelines

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Neu im Fachgebiet Allgemeinmedizin

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO2. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Zeitschrift für Allgemeinmedizin, DEGAM

RAS-Blocker bei Hyperkaliämie möglichst nicht sofort absetzen

14.05.2024 Hyperkaliämie Nachrichten

Bei ausgeprägter Nierenfunktionsstörung steigen unter der Einnahme von Renin-Angiotensin-System(RAS)-Hemmstoffen nicht selten die Serumkaliumspiegel. Was in diesem Fall zu tun ist, erklärte Prof. Jürgen Floege beim diesjährigen Allgemeinmedizin-Update-Seminar.

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise